CVRx develops an implantable system that delivers baroreflex activation therapy to rebalance the autonomic nervous system and improve symptoms of chronic heart failure. The device stimulates natural pressure sensors in the carotid artery to help reduce stress on the heart and enhance exercise capacity and quality of life for patients not adequately helped by standard therapies.

IPO in June 2021 (NASDAQ: CVRX).